|Title||ACCESS CHINA Biotech Forum|
|Category||CEO Story |
PharmAbcine, a clinical-stage biotech company focusing on the development of next- generation antibody therapeutics, announced today that the Company will virtually participate in ACCESS CHINA Biotech Forum taking place from September 23-30, 2021.
ACCESS CHINA Biotech Forum is one of the largest corporate access events in China that provides opportunities for business development, licensing deals, or commercial collaborations to global pharmas.
During the event, PharmAbcine’s pre-recorded presentation video, which updates the R&D progress of the main pipelines such as olinvacimab, PMC-403, and PMC-309, will be made available to global pharmas that are looking to enrich their pipelines through in-licensing deals.
■ Visit the link below for more information about the event